References

1. Carruthers A, Kiene K, Carruthers J (1996) Botulinum A exotoxin use in clinical dermatology. J Am Acad Dermatol 34(5) : 788–797

2. Tintner R, Jankovic J (2001) Focal dystonia: the role of botulinum toxin. Curr Neurol Neurosci Rep 1(4) : 337–345

3. Smith ME, Ford CN (2000) Resistance to botulinum toxin injections for spasmodic dysphonia. Arch Otolaryngol Head Neck Surg 126(4) : 533–535

4. Siatkowski RM et al (1993) Serum antibody production to botulinum A toxin. Ophthalmology 100(12) : 1861–1866

5. Elan Pharmaceutical Inc (2000) Myobloc package insert

6. Guttman C (2002) Botulinum toxin type B option for wrinkles, sweating.Dermatology Times

7. Foster JA et al (1996) The use of botulinum A toxin to ameliorate facial kinetic frown lines. Ophthalmology 103(4) : 618–622

8. Scott AB,Rosenbaum A,Collins C (1973) Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 12(12) : 924–927

9. Naumann M, Lowe NJ (2001) Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised parallel group double blind placebo controlled trial. BMJ 323(7313) : 596–599

10. Borodic GE, Cheney M,McKenna M (1992) Contralateral injections of botulinum A toxin for the treatment of hemifacial spasm to achieve increased facial symmetry. Plast Reconstr Surg 90(6) : 972–979

11. Lowe NJ,Maxwell A, Harper H (1996) Botulinum A exotoxin for glabellar folds: a double-blind placebocontrolled study with an electromyographic injection technique. J Am Acad Dermatol 35(4) : 569–572

12. Blitzer A et al (1997) The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. Arch Otolaryngol Head Neck Surg 123(4) : 389–392

13. Fodor P, Nicanor GI, Hengst TC (1996) Endoscopically assisted plastic surgery.Mosby, St Louis

14. Allergan Pharmaceuticals (2002) Botox Cosmetic (botulinum toxin type A). Prescribing information

15. Carruthers A, Carruthers J (1994) Botulinum toxin used in the treatment of glabellar frown lines and other facial wrinkles. In: Jankovic J, Hallett M (eds) Therapy with botulinum toxin.Marcel Dekker,New York, pp 577–595

16. Dysport Cbotulinum type A toxin-haemagglutinin complex: patient information leaflet


17. Elan Pharmaceuticals (2004) Myobloc: Cosmetic use

18. Sadick NS, Faacs (2002) Botulinum toxin type B for glabellar wrinkles: a prospective open-label response study. Dermatol Surg 28(9) : 817–821

19. Sadick NS (2003) Prospective open-label study of botulinum toxin type B (Myobloc) at doses of 2400 and 3000 U for the treatment of glabellar wrinkles. Dermatol Surg 29(5) : 501–507

20. Spencer JM, Gordon M, Goldberg DJ (2002) Botulinum B treatment of the glabellar and frontalis regions: a dose response analysis. J Cosmet Laser Ther 4(1) : 19–23

21. Ramirez AL, Reeck J, Maas CS (2002) Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines. Otolaryngol Head Neck Surg 126(5) : 459–467

22. Alster TSL, Lupton J R (2003) Botulinum toxin type B for dynamic glabellar rhytides refractory to botulinum toxin type A. Dermatol Surg 29(5) : 516–518

23. Lowe NJ et al (2002) Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing. J Cosmet Laser Ther 4(1) : 15–18

24. Flynn TC, Clark RE (2003) 2nd Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 29(5) : 519–522

25. Baumann L et al (2003) A double-blinded randomized placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B)-purified neurotoxin complex for the treatment of crow’s feet: a double-blinded placebo-controlled trial. Dermatol Surg 29(5) : 508–515

26. Matarasso SL (2003) Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 29(1) : 7–13

27. Borodic G (1998) Myasthenic crisis after botulinum toxin Lancet 352(9143) : 1832

28. Erbguth F et al (1993) Systemic effect of local botulinum toxin injections unmasks subclinical Lambert- Eaton myasthenic syndrome J Neurol Neurosurg Psychiatry 56(11) : 1235–1236

29. ATC Draft (2001) Facial aesthetic enhancements: chemodenervation and tissue augmentation pp 76

30. Finn JC (2004) Botulinum toxin type A: fine-tuning treatment of facial nerve injury. J Drugs Dermatol

3(2) : 133–137 31. Flynn TC, Carruthers, JA (2001) Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg 27(8) : 703–708

32. Carruthers J, Carruthers A (2001) BOTOX use in the mid and lower face and neck. Semin Cutan Med Surg 20(2) : 85–92

33. Becker-Wegerich PM, Rauch L, Ruzicka T (2002) Botulinum toxin A: successful décolleté rejuvenation. Dermatol Surg 28(2) : 168–171


34. Scott AB, Suzuki D (1988) Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 3(4) : 333–335

35. Lange DJ et al (1991) Distant effects of locally injected botulinum toxin: a double-blind study of single fiber EMG changes.Muscle Nerve 14(7) : 672–675

36. Girlanda P et al (1992) Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 55(9) : 844–845